| JASMINE LEUNG, RN BSN Education: |
||
| University of Tennessee, Knoxville, Tennessee Bachelor of Science in Nursing, June 1980 |
||
| Professional Experience: |
||
| Clinical Coordinator, Research Study Coordinator & Clinical Associate for Cosmetic Services, Suzanne Bruce and Associates, P.A., 1900 St. James Place, Suite 650, Houston, Texas 77056; 2/99 to present. Supervises all clinical activities for this three-doctor, three-office dermatology practice. Performs and supervises certain cosmetic procedures. Responsible for coordinating and conducting all phases of clinical research studies. Clinical Research Coordinator, University of Texas Health Science Center, Department of Dermatology, Houston, Texas; 7/95 to 2/99. Responsible for coordinating and conducting all phases of clinical research studies including interaction with sponsors, preparation of regulatory documents, Institutional Review Board approvals, budgets, and preparation of contracts and financial agreements for University of Texas approval. Research Nurse, Department of Dermatology Clinical Research Center, University of Texas at Houston; August 1993 to present. Evaluating patients according to study protocols. Dispensing and tracking study medications. Assuring patient compliance with study drugs and protocols. Assisting Clinical Research Coordinator with regulatory requirements for studies. RN, Skin Disease Treatment Center, Hermann Hospital, Houston, Texas; January 1990 to present. Working independently administering treatment for moderate to severe psoriasis patients on an outpatient basis. RN, Pain Center, Hermann Hospital, Houston, Texas; March 1987 to December 1989. RN, Peritoneal Dialysis, Hermann Hospital, Houston, Texas; March 1986 to 1987. Specialized in training outpatient dialysis; Wrote protocols for cross-training nurses within Texas Kidney Institution and other units; Developed audio-visual projects, checklists and procedures for CAPD and CCPD; Participated in research to determine the retention ratio of patient in Peritoneal Dialysis. RN, Renal Transplant and RICU, Hermann Hospital, Houston, Texas; July 1984 to March 1986. Assisted in developing primary nursing system for both units; Restructured the classification codes for the best quantity and quality care of patient for both Renal Transplant Unit and RICU; Assisted with research on cyclosporine level on work-up patients, and effects of OKT and prednisone on patients. RN, Oncology Unit, Hermann Hospital, Houston, Texas; July 1983 to July 1984. Specialized in patient teaching on side effects of chemotherapy, radiotherapy, and pain therapy. Assisted with research on new investigational chemotherapy. RN, Oncology Unit and Adult Hospices, Baptist Medical Center, Little Rock, Arkansas; August 1982 to June 1983. Taught side effects of chemotherapy to patients, assisted in Home Visits and taught home self-care. RN, Upjohn Health Care Services, Lansing, Michigan; January 1981 to July 1982. Administered Home Health Care procedures and taught same to family and patients. RN, Medical Surgical Unit, East Tennessee Children’s Hospital, Knoxville, Tennessee; June 1980 to December 1980. Preoperative and post-operative teaching to parents of pediatric patients. X-Ray Technician, East Tennessee Children’s Hospital, Knoxville, Tennessee; September 1976 to May 1980. Nurse Technician, Presbyterian Hospital, Knoxville, Tennessee; September 1976 to May 1980. |
||
| Memberships/Certifications: |
||
| Certificate of Critical Care Certificate of Emergency Procedure Certificate of EKG Certificate of CPR Certificate of Chemotherapy Texas Gulf Coast DNA Treasurer Committee of Primary Nursing Committee of PACE Committee of Task Force Clinical Ladder Committee Member Dermatology Nurses Association |
||
| Clinical Research: |
|
| 1. | The Role of Hydrocolloid Dressings in Prevention of Post Surgical Wound Infection in Obstetrics and Gynecology Patients, 9/25/96 - Present. |
| 2. | Multi-Center Tinea Capitis Epidemiology Study, 4/19/96 - Present. |
| 3. | Randomized Phase 3 Vehicle Controlled Trial of ALRT1057 Topical Gel in Patients with AIDS-Related Cutaneous Kaposi’s Sarcoma, 2/16/96 - Present. |
| 4. | Safety and Efficacy of Tazarotene 0.1% Gel Applied Once Daily for Two Weeks with Assessment of Molecular Markers Followed by Alternate Week Therapy for a Total of 15 Weeks in the Treatment of Plaque Psoriasis (Probe Study)”, Protocol 190168-003, 11/17/95 - Present. |
| 5. | Phase 1-2 Evaluation of Topical LGD1069 in Patients with Cutaneous Kaposi’s Sarcoma, Ligand Pharmaceuticals, Protocol L1069-94-03T, 6/94 - Present. |
| 6. | Phase 1-2 Evaluation of Topical LGD1057 in Patients with Cutaneous Kaposi’s Sarcoma, Ligand Pharmaceuticals, Protocol L1057-94-02T, 6/94 - Present. |
| 7. | Pathogenesis and Therapy of HIV Related Psoriasis, HSC-MS-92-116, NIH Grant. 7/93 - Present. |
| 8. | Analysis of New Epidermal proteins: Function and Regulation in normal Skin and in Psoriasis, HSC-MS-84-108. 4/93 - Present. |
| 9. | An Open-Label Study to Evaluate Oral Famciclovir for the Management of Herpes Simplex in Immunocompetent and Immunocompromised Patients who have Responded Inadequately to Oral Acyclovir or Valacyclovir. SmithKline Beecham. 07/98. |
| 10. | Multi-center Evaluation of the Safety and Efficacy of CP-80,633 Ointment, 0.5% versus Vehicle and DESOWEN (desonide) Ointment, 0.05% for the Treatment of Atopic Dermatitis, 2/16/96 - 11/13/96. |
| 11. | Regimen Efficacy Comparison of DESOWEN Lotion vs DESOWEN Lotion plus CETAPHIL Moisturizing Cream in Patients with Atopic Dermatitis, Galderma, Protocol CR.U9504. 8/18/95 - 3/28/96. |
| 12. | A Multi-Center, Double-Blind, Parallel Group Efficacy and Safety Comparison of Ifetroban and Placebo in Patients with Venous Leg Ulcers, Convatec/BMS, Protocol CV 139-001. 8/31/95 - 97. |
| 13. | Phase III-IV Studies to Evaluate Butenafine HCL in the Treatment of Tinea Pedis, Tinea Corporis, Tinea Cruris, and Onychomycosis. Penederm Inc., Spring 1995 - July 1996. |
| 14. | Long-term Safety of UVB and PUVA therapies for Treatment of Skin Disease in HIV-infected Patients. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. 11/7/94 - 3/10/95. |
| 15. | A Double Blind, Randomized, Vehicle-Controlled Crossover Study Evaluating the Safety and Efficacy of Topical Naloxone Lotion, 0.2%, in Subjects with Pruritic Mycosis Fungoides or Sezary Syndorme, GenDerm Corporation, Protocol 1013-2721-05, 8/19/94 - 5/12/95. |
| 16. | An Open Label, Compassionate Use Study Monitoring the Long Term Safety and Efficacy of Topical Naloxone Lotion, 0.2%, in Subjects with Pruritic Mycosis Fungoides or Sezary Syndrome, GenDerm Corporation, Protocol 1013-2721-06, 7/94 - 10/23/95. |
| 17. | “A Double-Blind Randomized Study to Assess the Quality of Life and Cost of Disease in Patients with Herpes Zoster Treated with Famciclovir or Placebo”, SmithKline Beecham, Protocol No. 42810/123. 7/1/94 - 8/31/95. |
| 18. | A Double-Blind, Randomized, Parallel Group Placebo-Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Intravenous Lipo PGE1 Therapy in Patients with Ischemic Ulcers Due to Peripheral Vascular Disease, ALPHA Corp., Protocol ATC 92-12. 5/94 - 1/29/96. |
| 19. | An Open Label, Compassionate Use Study Monitoring the Long Term Safety and Efficacy of Topical Naloxone Lotion, 0.5%, in Subjects with Pruritic Mycosis Fungoides or Sezary Syndorme, GenDerm Corporation, Protocol 1013-2721-03, 5/20/94 - 5/12/95. |
| 20. | A Double Blind, Randomized, Vehicle-Controlled Crossover Study Evaluating the Safety and Efficacy of Topical Naloxone Lotion, 0.5%, in Subjects with Pruritic Mycosis Fungoides or Sezary Syndorme, GenDerm Corporation, Protocol 1013-2721-02, 5/20/94 - 10/27/94. |
| 21. | The Role of DNA Repair in Cutaneous Malignant Melanoma. University of Texas M.D. Anderson Cancer Center with Dr. Quingyi Wei, M.D., PH.D. 4/94 - 7/97. |
| 22. | A Phase III, Double-Blind, Placebo-Controlled Clinical Evaluation of Recombinant Human Platelet-Derived Growth Factor (rhPDGF-B) in the Healing of Chronic, Lower-Extremity Diabetic Ulcers After 20 Weeks Treatment. Robert Wood Johnson Pharmaceutical Research Institute, Protocol No. 92-22120-K. 12/15/93 - 96. |
| 23. | Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of Topically Applied E. coli-Derived rPDGR-BB in the Treatment of Venous Stasis Ulcers. Pharmaco Dynamics Research Inc.,/Amgen Inc., Protocol No. PDGF-9111; 10/3/93 - 7/29/94. |
| 24. | The Safety and Efficacy of AGN 190168 0.1% Gel Versus Vehicle Gel in Stable Plaque Psoriasis and Effect on Molecular Markers in Treated Plaque Psoriasis, Allergan, Inc., Protocol R168-106-8606. 9/93 - 9/96. |
| 25. | Evaluation of Famciclovir vs Placebo on Herpes Zoster Induced Pain (including Post-Herpetic), A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-center Study. SmithKline Beecham, Protocol No. FAM-067. 10/16/92 - 9/7/94. |
| 26. | The Efficacy and Safety of Orally Administered SQ 32, 756 in the Treatment of Acute, Localized, Non-Trigeminal Zoster in Immunocompetent Patients, Protocol 32, 793-15. 07/30/90 - 02/28/91. |
| 27. | Investigation of Psori-Med Synthetic Salt Mixture in Combination with Ultraviolet Therapy in the Treatment of Psoriasis, Psori-Med America. 12/01/88 - 12/89. |
| 28. | “A Multi-center, Open-Label Clinical Trial to Evaluate the Safety of Sandimmune in a Demographically Diverse Population of Patients with Severe Recalcitrant Plaque Psoriasis”, Sandoz Pharmaceuticals Corporation, Protocol CSF-503. |
| 29. | “A Randomized, Double-Blind, Parallel Group Dose Ranging Comparison of the Efficacy and Safety of Calcipotriene Solution in the Treatment of Scalp Psoriasis (Trial I), Bristol-Myers Squib, Protocol DE127-031. |
| 30. | “A Comparative Study of the Safety and Efficacy of Calcium Mupirocin with Cephalexin in the Treatment of Secondary Eczema”, SmithKline Beecham, Protocol BAC-130. |
| 31. | “A Comparative Study of ConvaTec Paste versus Standard Treatment (Saline Impregnated Gauze) in the Treatment of Wound Dehiscence in OB/GYN Patients”, ConvaTec, Hebert, Ali, Katz, and Lopez. |
| 32. | “Evaluation of Famciclovir vs Placebo on Herpes Zoster Induced Pain (including Post-Herpetic), A Double-Blind, Placebo-Controlled, Parallel Group, Multi-center Study”, SmithKline Beecham, Protocol FAM-067. |
| 33. | “Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of Penciclovir (1%) Cream with Placebo in Recurrent Herpes Simplex Labialis”, SmithKline Beecham, Protocol PDGF-9111. |
| 34. | “Safety, Efficacy, and Duration Of Therapeutic Effect of Once Daily AGN 190168 0.1% Gel or 0.05% Gel vs Vehicle Gel in Stable Plaque Psoriasis”, Allergan, Protocol r168-106-8606. |
| 35. | “Safety of Nonaqueous 2.5% Topical Minoxidil Solution with 10% SEPA in the Treatment of Androgentic Alopecia in Women”, UpJohn, Protocol M7415/0038. |
| 36. | “Assessment of Topical Isotretinoin Crease in the Treatment of Patients with Photodamaged Skin”, Hoffman-LaRoche, Protocol N3684C. |
| 37. | “The Safety and Efficacy of AGN 190168 0.1% Gel vs Vehicle Gel in Stable Plaque Psoriasis and Effect on Molecular Markers in Treated Plaque Psoriasis”, Allergan Inc., Protocol R168-106-8608. |
| 38. | Pathogenesis and Therapy of HIV Related Psoriasis”, HSC-MS-92-116. |
| 39. | “Analysis of New Epidermal proteins: Function and Regulation in normal Skin and in Psoriasis, HSC-MS-84-108. |
| 40. | “Retrovir Capsules for the Treatment of Non-HIV Patients with Psoriasis”, Burroughs Wellcome, Protocol B92-MC-AQAW. |
| 41. | “An Open-Label Study to Evaluate Oral Famciclovir for the Suppression of Recurrent Genital Herpes in HIV-Infected Patients” Protocol SKB 42810/195. |
| 42. | “A Phase III, Randomized, Double-Blind, Study Comparison of Topically Applied Tacrolimus Ointment VS. Vehicle Ointment in Adult Patients with Atopic Dermatitis” Fujisawa Protocol #97-0-036. |
| 43. | “An Open-Label Study to Evaluate Oral Famciclovir for the Management of Herpes Simplex in Immunocompetent and Immunocompromised Patients who have Responded Inadequately to Oral Acyclovir or Valacyclovir” SKB Protocol #42810/198. |
| 44. | “A Multi-Center, Double-Blind, Parallel group Efficacy and Safety Comparison of Ifetroban and Placebo in Patients with Venous Leg Ulcers” Bristol/Myers Protocol #CV-139-001. |
| 45. | “A Multi-center Evaluation of the Safety and Efficacy of CP-80,633 Ointment, 0.5% versus Vehicle and DesOwen (desonide) Ointment, 0.05% for the Treatment of Atopic Dermatitis.” Galderma Protocol. |
| 46. | “A Long-Term Non-Comparative Trial to Evaluate the Safety of Topically Applied Tacrolimus as Treatment of Atopic Dermatitis in Pediatric Patients” Fujisawa Protocol #96-0-025. |
| 47. | “An Open-Label Study to Evaluate Oral Famciclovir for the Suppression of Recurrent Genital Herpes in HIV-Infected Patients” SKB Protocol MS-96-224. |
| 48. | “A Double-Masked, Double-Dummy, Randomized, Acyclovir Controlled, Parallel Group Study to Compare the Efficacy and Safety of Famciclovir with Acyclovir in the Treatment of Patients with Ophthalmic Zoster” SKB Protocol #41810-098. |
| 49. | “A Comparative Study of ConvaTec Gel versus Standard Treatment (Saline Impregnated Gauze) in the Treatment of Wound Dehiscence in Obstetrical and Gynecological Patients with Abdominal Wound Dehiscence” Convatec Protocol. |
| 50. | “A Phase II, Multi-center, Double-Blinded, Placebo-Controlled, Randomized, Parallel Group Study to Compare the Safety and Efficacy of Two Different Daily Doses of Zemaphyte Eczema Granules (P1FP) in the Treatment of Severe, Dry Atopic Dermatitis” Phytopharm Protocol #P1/06CR/96/4. |
| 51. | A Randomized, Double-Blind, Multi-center, Comparative Study of Gatifloxacin Versus Levofloxacin in the Treatment of Uncomplicated Skin and Soft Tissue Infections” Bristol Myers Protocol AI420-005. |
| 52. | A Randomized, Double-Blind, Multi-center, Comparative Study of Gatifloxacin Versus Levofloxacin in the Treatment of Uncomplicated Skin and Soft Tissue Infections. PPD Pharmaco. |
| 53. | An Open Label Adrenal Suppression Study of Fluticasone Propionate Ointment 0.005% used twice daily in pediatric subjects aged 3 months to 2 years with moderate to severe eczema or psoriasis. Protocol No. FLTA-4014, IND No. 28,765. |
| 54. | A Phase III, Randomized, Double-Blind, Study Comparison or Topically Applied Tacrolimus Ointment vs. Vehicle Ointment in Adult Patients with Atopic Dermatitis. Fujisawa, USA, Inc. Protocol 96-0-035. |
| 55. | “A Multi-Center Investigator-Masked Study of the Hypopigmentation Potential of Azelaic Acid 20% Cream vs. Tretinoin 0.025% Cream in Dark-Complexioned Patients (Skin Types IV, V, VI) with Mild to Moderate Acne” Allergan Protocol #191861-003. |
| 56. | “A Clinical Evaluation of the Dyna-Flex Multi Layered Compression System compared to the Unna’s Boot in Healing of Venous Ulcers” Johnson & Johnson Protocol GC-97-14/3962. |
| 57. | “An open-label adrenal suppression study of fluticasone propionate cream 0.05% used twice daily in pediatric subjects aged 3 to 5 years with moderate to severe eczema or psoriasis” Glaxo-Wellcome Protocol FPC 40001. |
| 58. | “An open-label adrenal suppression study of fluticasone propionate ointment 0.05% used twice daily in pediatric subjects aged 3 months - 2 years with moderate to severe eczema or psoriasis. Glaxo-Wellcome Protocol FPO 40001. |
| 59. | “Efficacy of Dermazinc Baby for Cradle Cap” DermaLogix, Inc. |
713.985.0210